Logo image of LIPO

LIPELLA PHARMACEUTICALS INC (LIPO) Stock Fundamental Analysis

NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD

2.36  -0.35 (-12.75%)

After market: 1.8001 -0.56 (-23.72%)

Fundamental Rating

2

Taking everything into account, LIPO scores 2 out of 10 in our fundamental rating. LIPO was compared to 555 industry peers in the Biotechnology industry. While LIPO has a great health rating, there are worries on its profitability. LIPO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LIPO had negative earnings in the past year.
In the past year LIPO has reported a negative cash flow from operations.
LIPO had negative earnings in each of the past 5 years.
LIPO had a negative operating cash flow in each of the past 5 years.
LIPO Yearly Net Income VS EBIT VS OCF VS FCFLIPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

With a Return On Assets value of -105.66%, LIPO is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
LIPO's Return On Equity of -125.78% is in line compared to the rest of the industry. LIPO outperforms 40.86% of its industry peers.
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROIC N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
LIPO Yearly ROA, ROE, ROICLIPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

LIPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIPO Yearly Profit, Operating, Gross MarginsLIPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

7

2. Health

2.1 Basic Checks

LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LIPO has been increased compared to 1 year ago.
Compared to 5 years ago, LIPO has less shares outstanding
There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LIPO Yearly Shares OutstandingLIPO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
LIPO Yearly Total Debt VS Total AssetsLIPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of 0.93, we must say that LIPO is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.93, LIPO is doing good in the industry, outperforming 65.59% of the companies in the same industry.
There is no outstanding debt for LIPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.93
ROIC/WACCN/A
WACC8.93%
LIPO Yearly LT Debt VS Equity VS FCFLIPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

A Current Ratio of 6.21 indicates that LIPO has no problem at all paying its short term obligations.
LIPO's Current ratio of 6.21 is fine compared to the rest of the industry. LIPO outperforms 62.01% of its industry peers.
A Quick Ratio of 6.21 indicates that LIPO has no problem at all paying its short term obligations.
LIPO has a better Quick ratio (6.21) than 62.54% of its industry peers.
Industry RankSector Rank
Current Ratio 6.21
Quick Ratio 6.21
LIPO Yearly Current Assets VS Current LiabilitesLIPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

LIPO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -56.74%.
Looking at the last year, LIPO shows a quite strong growth in Revenue. The Revenue has grown by 8.88% in the last year.
Measured over the past years, LIPO shows a decrease in Revenue. The Revenue has been decreasing by -5.04% on average per year.
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%

3.2 Future

Based on estimates for the next years, LIPO will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.87% on average per year.
LIPO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -41.42% yearly.
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LIPO Yearly Revenue VS EstimatesLIPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
LIPO Yearly EPS VS EstimatesLIPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LIPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LIPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIPO Price Earnings VS Forward Price EarningsLIPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIPO Per share dataLIPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as LIPO's earnings are expected to grow with 19.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.97%
EPS Next 3Y19.87%

More info and screens

0

5. Dividend

5.1 Amount

LIPO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIPELLA PHARMACEUTICALS INC

NASDAQ:LIPO (6/18/2025, 8:03:30 PM)

After market: 1.8001 -0.56 (-23.72%)

2.36

-0.35 (-12.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)N/A N/A
Inst Owners1.41%
Inst Owner Change-78.87%
Ins Owners6.52%
Ins Owner Change0%
Market Cap10.55M
Analysts82.86
Price Target10.2 (332.2%)
Short Float %1.6%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.29
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-17.77
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.12
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.66%
ROE -125.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.13%
ROA(5y)-91.9%
ROE(3y)-154.59%
ROE(5y)-121.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.21
Quick Ratio 6.21
Altman-Z 0.93
F-Score5
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-56.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.42%
EPS Next Y33.76%
EPS Next 2Y-48.97%
EPS Next 3Y19.87%
EPS Next 5YN/A
Revenue 1Y (TTM)8.88%
Revenue growth 3Y27.4%
Revenue growth 5Y-5.04%
Sales Q2Q%-11.31%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.41%
OCF growth 3YN/A
OCF growth 5YN/A